One detail that explains a lot about how modern peptide drugs work, and why some need daily injections while others last a week or a month, is what chemists do to extend a peptide's half-life after it's injected. This site's guide to how peptides work in the body covers half-life at a general level; this piece looks specifically at the engineering techniques behind it.

Why Natural Peptides Don't Last Long

Most naturally occurring peptide hormones are built to be short-lived. Native GLP-1, for example, has a half-life of only about two minutes in the body, rapidly broken down by an enzyme called DPP-4 and cleared by the kidneys. That's useful for a hormone meant to send brief, meal-triggered signals, but it's a problem for turning that same molecule into a practical once-weekly drug like semaglutide or tirzepatide.

Technique One: Fatty Acid Conjugation

Fatty acid conjugation, sometimes called acylation, attaches a fatty acid side chain to the peptide backbone, usually via a small chemical linker. This works through two mechanisms: the fatty acid chain allows the peptide to reversibly bind to albumin, the most abundant protein in blood plasma, which acts as a slow-release reservoir and also protects the peptide from enzymatic breakdown while it's bound. Semaglutide and liraglutide, both discussed elsewhere on this site, use fatty acid conjugation, which is a major reason semaglutide's half-life runs about one week compared to native GLP-1's roughly two minutes.

Technique Two: PEGylation

PEGylation attaches strands of polyethylene glycol (PEG), a chemically inert, water-soluble polymer, to a peptide. The large PEG molecule increases the overall size of the peptide-PEG complex, which slows kidney filtration (the kidneys filter based partly on molecular size) and can also shield the peptide from enzymatic degradation. PEGylation was one of the earlier half-life extension technologies used across biologic drugs generally, not just peptides, though it's less commonly the primary approach in the newest generation of metabolic peptide drugs, which tend to favor fatty acid conjugation or Fc-fusion instead.

Technique Three: Fc-Fusion

Fc-fusion attaches a peptide to the Fc (fragment crystallizable) region of an antibody, the same structural piece that gives full antibody drugs their characteristically long half-lives, often measured in weeks. Fc-fusion peptides can piggyback on a recycling pathway called the neonatal Fc receptor (FcRn) system, which the body normally uses to preserve antibodies from being broken down, extending the fused peptide's circulation time substantially. Dulaglutide (Trulicity) is a well-known example that uses this approach.

Why the Distinction Matters

These aren't just chemistry trivia. The half-life extension method used affects dosing frequency, how a drug is stored and administered, how quickly its effects wear off if a dose is missed or stopped, and sometimes its side-effect profile, since the extension technology itself (not just the core peptide) can occasionally trigger immune responses, particularly with PEGylation in a subset of patients who develop anti-PEG antibodies over repeated exposure.

How This Applies to Research-Chemical Peptides

It's worth noting that most unapproved research-chemical peptides discussed elsewhere on this site, compounds like BPC-157 or TB-500, don't use any of these half-life extension technologies. They're typically the unmodified, short-half-life native peptide sequence, which is part of why questions about dosing frequency and duration of effect for those compounds remain largely unanswered by rigorous human data.

The Bottom Line

Fatty acid conjugation, PEGylation, and Fc-fusion are the three main chemistry tools that turn a fragile, minutes-long peptide signal into a practical once-weekly or once-monthly injectable drug. Understanding which technique a given drug uses helps explain its dosing schedule, and it's a useful lens for understanding why an FDA-approved, chemically engineered peptide drug behaves very differently in the body than an unmodified research-chemical peptide with the same core amino acid sequence.